[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100626250":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":13,"locations":19,"responsibleParty":32,"collaborators":7,"id":34,"slug":35,"hasResults":36,"nctId":37,"briefTitle":38,"officialTitle":39,"acronym":40,"eligibilityCriteria":41,"healthyVolunteers":36,"sex":42,"minAge":43,"maxAge":7,"enrollmentInfo":44,"targetDuration":7,"studyType":47,"phases":7,"briefSummary":48,"conditions":49,"keywords":7,"overallStatus":22,"whyStopped":7,"lastUpdateSubmitDate":51,"lastUpdatePostDateStruct":52,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":59,"locationsCount":60},{"fullName":5,"class":6},"Servier Russia","INDUSTRY",null,[9],{"name":10,"affiliation":11,"role":12},"Marina Shestakova","Endocrinology Research Centre","PRINCIPAL_INVESTIGATOR",[14],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},"Ekaterina Erina","CONTACT","+7 495 9370700","ekaterina.erina@servier.com",[20],{"facility":21,"status":22,"city":23,"state":7,"zip":7,"country":24,"countryCode":25,"cosmosGeoPoint":26,"geoPoint":31,"contacts":7},"GBUZ hospital","RECRUITING","Anapa","Russia","RU",{"type":27,"coordinates":28},"Point",[29,30],37.31623,44.89497,{"lat":30,"lon":29},{"type":33,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100626250","polus-description-of-the-effectiveness-and-tolerability-of-luseogliflozin-in-patients-with-type-2-diabetes-100626250",false,"NCT07433192","POLUS: Description of the Effectiveness and Tolerability of Luseogliflozin in Patients With Type 2 Diabetes.","Multicenter Observational Study POLUS: Description of the Effectiveness and Tolerability of Luseogliflozin in Patients With Type 2 Diabetes in Real-world Clinical Practice.","POLUS","Inclusion Criteria:\n\n* Men and women aged 18 years and older.\n* Patients with type 2 diabetes.\n* Written informed consent of the patient to participate in the study.\n* No conditions that require emergency medical aid.\n* Treatment with luseogliflozin started 7 to 30 days prior to the inclusion visit as part of routine clinical practice and in accordance with the SmPC approved in the Russian Federation.\n* Presence of data on the parameters of interest (HbA1c, eGFR, BP, body weight), dated no later than 15 days from the date the treatment with luseogliflozin was started\n\nExclusion Criteria:\n\n* Patients cannot be included in this study if they meet at least one of the following exclusion criteria:\n* Known hypersensitivity to luseogliflozin or other components of Lusefi®.\n* Type 1 diabetes.\n* Decompensated type 2 diabetes.\n* Pregnancy, breastfeeding, or planned pregnancy during the study and at least two months after the study.\n* Severe renal failure (eGFR \\\u003C30 mL\u002Fmin\u002F1.73 m2), end-stage chronic kidney disease (CKD) or dialysis, as the treatment is predicted to be ineffective in this population of patients.\n* Diabetic ketoacidosis, diabetic coma or precoma.\n* Severe infections, pre- and postoperative period, or severe injury.\n* Any suspected or confirmed malignant neoplasm, including a history of malignancy within ≤5 years prior to screening, excluding successfully treated basal cell carcinoma and squamous cell carcinoma of the skin or in situ cervical cancer.\n* Urinary tract infection (confirmed or suspected).\n* Other concomitant disorders considered by the investigator to affect the natural progression of the disease and significantly impact the treatment results.\n* Predictable unwillingness of the patient to adhere to the treatment regimen and\u002For cooperate with the investigator.\n* Participation of the patient in another clinical study within 3 months (6 months for biological medicinal products) prior to the inclusion visit or during this study.","ALL","18 Years",{"count":45,"type":46},300,"ESTIMATED","OBSERVATIONAL","In this non-interventional study, the effectiveness and tolerability of Lusefi® in adult patients with type 2 diabetes will be evaluated.",[50],"Type 2 Diabetes Mellitus","2026-04-29",{"date":53,"type":54},"2026-04-30","ACTUAL",{"date":56,"type":54},"2026-03-02",{"date":58,"type":46},"2027-09-01",{"name":5,"class":6},1]